Respiratory – Page 11

MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management

By MedXY 09/21/2025

The MACRO trial demonstrates that endoscopic sinus surgery significantly improves quality of life in adults with chronic rhinosinusitis, while long-term low-dose clarithromycin shows no added benefit over placebo.

Clinical Updates HIV/AIDS news Respiratory

Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial

By MedXY 09/21/2025

A multicentre randomized trial evaluated adjunctive corticosteroids in HIV-negative severe Pneumocystis jirovecii pneumonia, showing a non-significant reduction in 28-day mortality and no safety concerns, and calls for further targeted research.

Clinical Updates Infectious Diseases news Respiratory Specialties

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

By MedXY 09/21/2025

The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, highlighting the need for longer, strengthened treatments.

news Respiratory

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

By MedXY 09/19/2025

Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.

news Respiratory Specialties

High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial

By MedXY 09/19/2025

The PROSA 2 trial demonstrates that high-flow nasal oxygen significantly reduces hypoxaemia time and events compared to conventional low-flow oxygen in COPD patients undergoing bronchoscopy, improving procedural safety without compromising patient comfort.

news Respiratory Specialties

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

By MedXY 09/19/2025

This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision therapy.

Clinical Updates news Respiratory

Low-Dose Morphine in COPD: Balancing Breathlessness Relief Against Sleep-Related Respiratory Risks

By MedXY 09/19/2025

A randomized crossover trial reveals low-dose morphine in COPD does not improve sleep efficiency or breathlessness but may cause nocturnal hypoventilation, raising safety concerns despite unchanged next-day alertness.

Clinical Updates news Respiratory

Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials

By MedXY 09/19/2025

Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.

Clinical Updates news Respiratory Specialties

Sustained Alterations in Glutamate Metabolism After Resistance Exercise in Older Adults With COPD and Healthy Controls

By MedXY 09/19/2025

Resistance exercise induces prolonged increases in glutamate production in older adults with COPD and healthy controls, highlighting unique metabolic adaptations that may influence pulmonary rehabilitation outcomes and muscle health.

news Respiratory Specialties

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

By MedXY 09/19/2025

The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients with frequent exacerbations, supporting ongoing phase 3 studies.

news Respiratory Specialties

Decoding Thoracoabdominal Asynchrony in Severe COPD: Insights Into Exercise Limitation and Respiratory Support

By MedXY 09/19/2025

This study reveals how thoracoabdominal asynchrony (TAA) during exercise reflects lung function severity and predicts breathlessness in very severe COPD patients, highlighting its potential to guide personalized respiratory support strategies during rehabilitation.

Clinical Updates news Respiratory

Enhancing Home Non-Invasive Ventilation Outcomes Through Real-World Telemonitoring: Insights from the eVENT Randomised Study

By MedXY 09/19/2025

The eVENT study demonstrates that telemonitoring combined with remote support significantly improves arterial CO2 control and home NIV adherence compared to usual care, highlighting a promising approach to optimize chronic respiratory failure management.

General Surgery news Respiratory Specialties

Riociguat Continuation After Balloon Pulmonary Angioplasty Preserves Exercise Capacity in Inoperable CTEPH: Insights from the THERAPY-HYBRID-BPA Trial

By MedXY 09/19/2025

The THERAPY-HYBRID-BPA study demonstrates that continuing riociguat after balloon pulmonary angioplasty maintains exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension without increasing adverse events.

Clinical Updates news Radiology Respiratory

Enhancing Hospitalist Care of Undifferentiated Dyspnea with Cardiopulmonary Point-of-Care Ultrasonography: Reducing Length of Stay and Costs

By MedXY 09/19/2025

Implementation of cardiopulmonary POCUS in hospitalist management of undifferentiated dyspnea significantly reduces hospital length of stay and costs, though adoption remains limited, highlighting the need for sustained training and support.

$Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications$

Clinical Updates news Respiratory Specialties

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

By MedXY 09/17/2025

The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential as a new therapeutic option.

Clinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY 09/17/2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Clinical Updates Infectious Diseases Respiratory Specialties

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY 09/17/2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Clinical Updates Infectious Diseases Respiratory Specialties

Evaluating Germicidal UV Light to Reduce Respiratory Infections in Long-Term Care: Insights from a South Australian Randomized Trial

By MedXY 09/10/2025

A randomized clinical trial in South Australian long-term care facilities found germicidal UV light appliances did not significantly reduce acute respiratory infection rates per cycle but modestly lowered total infections over time, suggesting a supportive role in infection control.

news Respiratory Specialties

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial

By MedXY 09/10/2025

A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.

Clinical Updates Internal Medicine news Public Health Respiratory Specialties

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY 09/06/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and atherosclerotic cardiovascular disease.